4mha

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 3: Line 3:
== Structural highlights ==
== Structural highlights ==
<table><tr><td colspan='2'>[[4mha]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4MHA OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4MHA FirstGlance]. <br>
<table><tr><td colspan='2'>[[4mha]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4MHA OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4MHA FirstGlance]. <br>
-
</td></tr><tr><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=4MH:2-(BUTYLAMINO)-4-[(TRANS-4-HYDROXYCYCLOHEXYL)AMINO]-N-(4-SULFAMOYLBENZYL)PYRIMIDINE-5-CARBOXAMIDE'>4MH</scene>, <scene name='pdbligand=CL:CHLORIDE+ION'>CL</scene>, <scene name='pdbligand=MG:MAGNESIUM+ION'>MG</scene><br>
+
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=4MH:2-(BUTYLAMINO)-4-[(TRANS-4-HYDROXYCYCLOHEXYL)AMINO]-N-(4-SULFAMOYLBENZYL)PYRIMIDINE-5-CARBOXAMIDE'>4MH</scene>, <scene name='pdbligand=CL:CHLORIDE+ION'>CL</scene>, <scene name='pdbligand=MG:MAGNESIUM+ION'>MG</scene></td></tr>
-
<tr><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[4m3q|4m3q]], [[3tcp|3tcp]], [[2brb|2brb]], [[3bpr|3bpr]], [[2poc|2poc]], [[4mh7|4mh7]]</td></tr>
+
<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[4m3q|4m3q]], [[3tcp|3tcp]], [[2brb|2brb]], [[3bpr|3bpr]], [[2poc|2poc]], [[4mh7|4mh7]]</td></tr>
-
<tr><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Receptor_protein-tyrosine_kinase Receptor protein-tyrosine kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.10.1 2.7.10.1] </span></td></tr>
+
<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Receptor_protein-tyrosine_kinase Receptor protein-tyrosine kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.10.1 2.7.10.1] </span></td></tr>
-
<tr><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4mha FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4mha OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4mha RCSB], [http://www.ebi.ac.uk/pdbsum/4mha PDBsum]</span></td></tr>
+
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4mha FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4mha OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4mha RCSB], [http://www.ebi.ac.uk/pdbsum/4mha PDBsum]</span></td></tr>
-
<table>
+
</table>
== Disease ==
== Disease ==
[[http://www.uniprot.org/uniprot/MERTK_HUMAN MERTK_HUMAN]] Defects in MERTK are the cause of retinitis pigmentosa type 38 (RP38) [MIM:[http://omim.org/entry/613862 613862]]. RP38 is a retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well.<ref>PMID:11062461</ref>
[[http://www.uniprot.org/uniprot/MERTK_HUMAN MERTK_HUMAN]] Defects in MERTK are the cause of retinitis pigmentosa type 38 (RP38) [MIM:[http://omim.org/entry/613862 613862]]. RP38 is a retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well.<ref>PMID:11062461</ref>
Line 18: Line 18:
Discovery of Mer specific tyrosine kinase inhibitors for the treatment and prevention of thrombosis.,Zhang W, McIver AL, Stashko MA, DeRyckere D, Branchford BR, Hunter D, Kireev D, Miley MJ, Norris-Drouin J, Stewart WM, Lee M, Sather S, Zhou Y, Di Paola JA, Machius M, Janzen WP, Earp HS, Graham DK, Frye SV, Wang X J Med Chem. 2013 Dec 12;56(23):9693-700. doi: 10.1021/jm4013888. Epub 2013 Nov, 20. PMID:24219778<ref>PMID:24219778</ref>
Discovery of Mer specific tyrosine kinase inhibitors for the treatment and prevention of thrombosis.,Zhang W, McIver AL, Stashko MA, DeRyckere D, Branchford BR, Hunter D, Kireev D, Miley MJ, Norris-Drouin J, Stewart WM, Lee M, Sather S, Zhou Y, Di Paola JA, Machius M, Janzen WP, Earp HS, Graham DK, Frye SV, Wang X J Med Chem. 2013 Dec 12;56(23):9693-700. doi: 10.1021/jm4013888. Epub 2013 Nov, 20. PMID:24219778<ref>PMID:24219778</ref>
-
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
+
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
</div>
</div>
 +
 +
==See Also==
 +
*[[Tyrosine kinase|Tyrosine kinase]]
== References ==
== References ==
<references/>
<references/>
Line 25: Line 28:
</StructureSection>
</StructureSection>
[[Category: Receptor protein-tyrosine kinase]]
[[Category: Receptor protein-tyrosine kinase]]
-
[[Category: Branchford, B R.]]
+
[[Category: Branchford, B R]]
-
[[Category: Deryckere, D.]]
+
[[Category: Deryckere, D]]
-
[[Category: Dipaola, J A.]]
+
[[Category: Dipaola, J A]]
-
[[Category: Earp, H S.]]
+
[[Category: Earp, H S]]
-
[[Category: Frye, S.]]
+
[[Category: Frye, S]]
-
[[Category: Graham, D K.]]
+
[[Category: Graham, D K]]
-
[[Category: Hunter, D.]]
+
[[Category: Hunter, D]]
-
[[Category: Janzen, W P.]]
+
[[Category: Janzen, W P]]
-
[[Category: Kireev, D B.]]
+
[[Category: Kireev, D B]]
-
[[Category: Lee, M.]]
+
[[Category: Lee, M]]
-
[[Category: Machius, M.]]
+
[[Category: Machius, M]]
-
[[Category: Mciver, A.]]
+
[[Category: Mciver, A]]
-
[[Category: Miley, D B.M.]]
+
[[Category: Miley, D B.M]]
-
[[Category: Norris-Drouin, J.]]
+
[[Category: Norris-Drouin, J]]
-
[[Category: Sather, S.]]
+
[[Category: Sather, S]]
-
[[Category: Stashko, M A.]]
+
[[Category: Stashko, M A]]
-
[[Category: Stewart, W M.]]
+
[[Category: Stewart, W M]]
-
[[Category: Wang, X.]]
+
[[Category: Wang, X]]
-
[[Category: Zhang, W.]]
+
[[Category: Zhang, W]]
-
[[Category: Zhou, Y.]]
+
[[Category: Zhou, Y]]
[[Category: Acute lymphoblastic leukemia]]
[[Category: Acute lymphoblastic leukemia]]
[[Category: Rational structure-based drug design]]
[[Category: Rational structure-based drug design]]
[[Category: Transferase-transferase inhibitor complex]]
[[Category: Transferase-transferase inhibitor complex]]
[[Category: Tyrosine kinase]]
[[Category: Tyrosine kinase]]

Revision as of 09:06, 5 January 2015

Crystal structure of the catalytic domain of the proto-oncogene tyrosine-protein kinase MER in complex with inhibitor UNC1817

4mha, resolution 2.59Å

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)

OCA

Personal tools